Company news

ACADIA Pharmaceuticals Inc. news in 2023

ACADIA Pharmaceuticals Inc.'s news releases, calls and decks from 2023, newest first.

View company

Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

December 20, 2023

Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation

December 12, 2023

Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)

December 12, 2023

Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

November 29, 2023

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis

November 26, 2023

Acadia Pharmaceuticals Announces Change in Research and Development Leadership

November 20, 2023

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

November 1, 2023

Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference

October 30, 2023

Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program

October 22, 2023

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023

October 18, 2023

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

September 18, 2023

Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview

August 1, 2023

Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer

July 23, 2023

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023

July 18, 2023

Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome

July 12, 2023

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome

June 12, 2023

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

June 7, 2023

Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 31, 2023

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

May 7, 2023

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 1, 2023

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

April 24, 2023

Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

April 19, 2023

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

April 16, 2023

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

March 9, 2023

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

February 26, 2023

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 13, 2023

Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development

January 8, 2023

Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics

January 2, 2023

Calls in 2023

Decks in 2023